Nature Reviews Rheumatology

Article	Citations
Synovial inflammation in osteoarthritis progression	406
Mechanisms and therapeutic implications of cellular senescence in osteoarthritis	371
Global epidemiology of systemic lupus erythematosus	344
Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA): updated treatment recommendations for psoriatic arthritis 2021	280
Janus kinase-targeting therapies in rheumatology: a mechanisms-based approach	252
Mechanisms of joint destruction in rheumatoid arthritis — immune cell–fibroblast–bone interactions	216
Systemic and organ-specific immune-related manifestations of COVID-19	211
The gut–joint axis in rheumatoid arthritis	210
Early-stage symptomatic osteoarthritis of the knee — time for action	189
A new immunometabolic perspective of intervertebral disc degeneration	183
Mechanosignalling in cartilage: an emerging target for the treatment of osteoarthritis	178
Toll-like receptor signalling in B cells during systemic lupus erythematosus	174
Ankylosing spondylitis: an autoimmune or autoinflammatory disease?	162
Global epidemiology of vasculitis	158
Multisystem inflammatory syndrome in children and Kawasaki disease: a critical comparison	157
Persistent inflammatory and non-inflammatory mechanisms in refractory rheumatoid arthritis	157
Cell-based strategies for IVD repair: clinical progress and translational obstacles	148
Epithelial–immune cell interplay in primary Sjögren syndrome salivary gland pathogenesis	148
The non-coding RNA interactome in joint health and disease	134
Autoinflammation and autoimmunity across rheumatic and musculoskeletal diseases	125
COVID-19 in people with rheumatic diseases: risks, outcomes, treatment considerations	118
Rheumatic disease and COVID-19: epidemiology and outcomes	117
Oral surveillance and JAK inhibitor safety: the theory of relativity	115
The endothelium–bone axis in development, homeostasis and bone and joint disease	113
Understanding and interpreting antinuclear antibody tests in systemic rheumatic diseases	104

Global epidemiology of rheumatoid arthritis	103
The decisive early phase of bone regeneration	99
TNF in the era of immune checkpoint inhibitors: friend or foe?	94
Current and future therapies for primary Sjögren syndrome	91
The evolution of nerve growth factor inhibition in clinical medicine	90
Evidence-Based Guideline for the diagnosis and management of eosinophilic granulomatosis with polyangiitis	85
Location, location, location: how the tissue microenvironment affects inflammation in RA	84
Synovial tissue macrophages in joint homeostasis, rheumatoid arthritis and disease remission	84
Immune cartography of macrophage activation syndrome in the COVID-19 era	83
Axial spondyloarthritis: concept, construct, classification and implications for therapy	79
Failure of cartilage regeneration: emerging hypotheses and related therapeutic strategies	77
Targeting interferon-γ in hyperinflammation: opportunities and challenges	73
Interleukin-2 and regulatory T cells in rheumatic diseases	73
State-of-the-art evidence in the treatment of systemic sclerosis	73
Treat-to-target in systemic lupus erythematosus: advancing towards its implementation	72
Treatment of axial spondyloarthritis: an update	69
Fatigue in inflammatory rheumatic diseases: current knowledge and areas for future research	69
Lyme arthritis: linking infection, inflammation and autoimmunity	68
IL-1 and autoinflammatory disease: biology, pathogenesis and therapeutic targeting	66
Excess comorbidities in gout: the causal paradigm and pleiotropic approaches to care	65
Psoriatic arthritis from a mechanistic perspective	65
Immune-checkpoint inhibitor use in patients with cancer and pre-existing autoimmune diseases	65
Cardiovascular effects of approved drugs for rheumatoid arthritis	64
Disorders of ubiquitylation: unchained inflammation	63
Why remission is not enough: underlying disease mechanisms in RA that prevent cure	63
Biological classification of childhood arthritis: roadmap to a molecular nomenclature	63
Insights into the biology and therapeutic implications of TNF and regulatory T cells	63
Vascular Behçet syndrome: from pathogenesis to treatment	63
Advances in epigenetics in systemic sclerosis: molecular mechanisms and therapeutic potential	62
Inflammation and DNA damage: cause, effect or both	56
Matrix metalloproteinases in arthritis: towards precision medicine	55
Immunogenicity of biologic agents in rheumatology	54
Interferon lambda in inflammation and autoimmune rheumatic diseases	53
MIS-C: early lessons from immune profiling	53
Treatment of lupus nephritis: consensus, evidence and perspectives	53
Genetics and epigenetics of primary Sjögren syndrome: implications for future therapies	50
Management of gout in chronic kidney disease: a G-CAN Consensus Statement on the research priorities	49
High risk of autoimmune diseases after COVID-19	49
The role of HIF proteins in maintaining the metabolic health of the intervertebral disc	49
Cartilage calcification in osteoarthritis: mechanisms and clinical relevance	49
Detection of microvascular changes in systemic sclerosis and other rheumatic diseases	48
Shared inflammatory pathways of rheumatoid arthritis and atherosclerotic cardiovascular disease	48
Molecular mechanisms of phenotypic variability in monogenic autoinflammatory diseases	48
Mechanisms and clinical implications of intervertebral disc calcification	48
Erosive hand osteoarthritis: latest findings and outlook	47
Rheumatoid sarcopenia: loss of skeletal muscle strength and mass in rheumatoid arthritis	46
Sex- and gender-related differences in psoriatic arthritis	45
Disease stratification in GCA and PMR: state of the art and future perspectives	45
Hypertension meets osteoarthritis — revisiting the vascular aetiology hypothesis	45
Joint distraction for osteoarthritis: clinical evidence and molecular mechanisms	43

Joint-on-chip platforms: entering a new era of in vitro models for arthritis	43
From risk to chronicity: evolution of autoreactive B cell and antibody responses in rheumatoid arthritis	43
An introduction to machine learning and analysis of its use in rheumatic diseases	42
Intervertebral disc degeneration and osteoarthritis: a common molecular disease spectrum	42
The role of neutrophils in rheumatic disease-associated vascular inflammation	40
Key opinion leaders — a critical perspective	40
Cellular metabolic adaptations in rheumatoid arthritis and their therapeutic implications	38
Acute exacerbation of interstitial lung disease associated with rheumatic disease	38
Rheumatic diseases in Africa	37
The role of mitochondria in rheumatic diseases	37
Glycobiology of rheumatic diseases	37
The impact of COVID-19 on rare and complex connective tissue diseases: the experience of ERN ReCONNET	35
Emotion regulation and the salience network: a hypothetical integrative model of fibromyalgia	34
Skin involvement in early diffuse cutaneous systemic sclerosis: an unmet clinical need	33
Precision medicine in systemic lupus erythematosus	33
International Guideline for Idiopathic Inflammatory Myopathy-Associated Cancer Screening: an International Myositis Assessment and Clinical Studies Group (IMACS) initiative	33
Immune cell dysregulation as a mediator of fibrosis in systemic sclerosis	32
Genetics of ANCA-associated vasculitis: role in pathogenesis, classification and management	32
Effects of targeted therapies on bone in rheumatic and musculoskeletal diseases	32
Biological and clinical roles of IL-18 in inflammatory diseases	31
Importance of lymphocyte–stromal cell interactions in autoimmune and inflammatory rheumatic diseases	30
Challenges in the management of older patients with inflammatory rheumatic diseases	30
Differentiating between UCTD and early-stage SLE: from definitions to clinical approach	28
Emerging concepts of type I interferons in SLE pathogenesis and therapy	28
Sphingosine 1-phosphate receptor-targeted therapeutics in rheumatic diseases	28
Immunological memory in rheumatic inflammation — a roadblock to tolerance induction	28
Consensus terminology for preclinical phases of psoriatic arthritis for use in research studies: results from a Delphi consensus study	28
Treat-to-target in axial spondyloarthritis — what about physical function and activity?	27
Regulation of activated T cell survival in rheumatic autoimmune diseases	27
Studying osteoarthritis with artificial intelligence applied to magnetic resonance imaging	26
How COVID-19 is changing rheumatology clinical practice	26
Juvenile idiopathic inflammatory myositis: an update on pathophysiology and clinical care	25
Sexual dimorphism in the prevalence, manifestation and outcomes of axial spondyloarthritis	25
Epidemiology of Sjögren syndrome	24
Precision medicine: the precision gap in rheumatic disease	24
Endothelial function and endothelial progenitor cells in systemic lupus erythematosus	23
Busting the myth of methotrexate chronic hepatotoxicity	23
Efficacy and safety of JAK inhibitors in rheumatoid arthritis: update for the practising clinician	23
Involvement of the secosteroid vitamin D in autoimmune rheumatic diseases and COVID-19	21
Mechanisms underlying the long-term and withdrawal effects of denosumab therapy on bone	21
Machine learning in precision medicine: lessons to learn	21
Targeting calcium-related mechanotransduction in early OA	19
Anti-MDA5 antibody-positive dermatomyositis: pathogenesis and clinical progress	18
Mechanisms and rationale for uricase use in patients with gout	18
New insights into the treatment of CTD-ILD	17
Systemic sclerosis gastrointestinal dysmotility: risk factors, pathophysiology, diagnosis and management	17
Diagnostic role of anti-dsDNA antibodies: do not forget autoimmune hepatitis	16
Therapeutic potential in rheumatic diseases of extracellular vesicles derived from mesenchymal stromal cells	16
TNF and TNF receptors as therapeutic targets for rheumatic diseases and beyond	15
Evidence-Based Guideline for the management of osteoporosis in men	15
Recent advances and evolving concepts in Still’s disease	14
Evolving concepts in systemic lupus erythematosus damage assessment	14
JAK inhibitors and VTE risk: how concerned should we be?	14
Heat of the night: sleep disturbance activates inflammatory mechanisms and induces pain in rheumatoid arthritis	13
Effect of DMARDs on the immunogenicity of vaccines	13
Rheumatoid arthritis prevention in arthralgia: fantasy or reality?	13
Spondyloarthritis with inflammatory bowel disease: the latest on biologic and targeted therapies	12
Assessment of disease outcome measures in systemic sclerosis	12
Age-related mechanisms in the context of rheumatic disease	12
Immune mechanisms of depression in rheumatoid arthritis	12
Mapping the musculoskeletal system one cell at a time	12
Engineering approaches for RNA-based and cell-based osteoarthritis therapies	12
Spectrum and impact of checkpoint inhibitor-induced irAEs	11
Genome editing to define the function of risk loci and variants in rheumatic disease	11
Striking a balance in rheumatoid arthritis prevention trials	11
Epidemiology of the idiopathic inflammatory myopathies	11
Phenotypic heterogeneity in psoriatic arthritis: towards tissue pathology-based therapy	11
When underlying biology threatens the randomization principle — initial gout flares of urate-lowering therapy	10
Back to the future: targeting the extracellular matrix to treat systemic sclerosis	10
Critical appraisal of serum urate targets in the management of gout	10
Pan American League of Associations for Rheumatology recommendations for the management of axial spondyloarthritis	9
Recent advancements in cartilage tissue engineering innovation and translation	9
New refinements aim to optimize articular cartilage tissue engineering	9
Systemic sclerosis interstitial lung disease: unmet needs and potential solutions	9
Hydroxychloroquine dose: balancing toxicity and SLE flare risk	9
The bone marrow side of axial spondyloarthritis	9
Predominant ligament-centric soft-tissue involvement differentiates axial psoriatic arthritis from ankylosing spondylitis	9
Kawasaki disease and MIS-C share a host immune response	8
Down syndrome: insights into autoimmune mechanisms	8
Post-transcriptional checkpoints in autoimmunity	8

New insights into RA genetics from GWAS meta-analysis	8
HIPPOCRATES: improving diagnosis and outcomes in psoriatic arthritis	8
Somatic mutations cause VEXAS syndrome	8
Complement therapeutics are coming of age in rheumatology	8
Towards a novel clinical outcome assessment for systemic lupus erythematosus: first outcomes of an international taskforce	8
Innate immune memory in inflammatory arthritis	7
The Musculoskeletal Knowledge Portal: improving access to multi-omics data	7
Author Correction: Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA): updated treatment recommendations for psoriatic arthritis 2021	7
Skin–kidney crosstalk in SLE	7
A comprehensive guide for managing the reproductive health of patients with vasculitis	7
Does psoriasis treatment affect PsA development?	7
Publisher Correction: Global epidemiology of systemic lupus erythematosus	7
Placebo effects in osteoarthritis: implications for treatment and drug development	7
IL-17A and IL-17F in tissue homeostasis, inflammation and regeneration	7